NASDAQ:PGNY - Nasdaq - US74340E1038 - Common Stock - Currency: USD
21.44
+0.04 (+0.19%)
The current stock price of PGNY is 21.44 USD. In the past month the price decreased by -1.11%. In the past year, price decreased by -34.43%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
UNH | UNITEDHEALTH GROUP INC | 16.24 | 415.38B | ||
ELV | ELEVANCE HEALTH INC | 12.88 | 96.11B | ||
HUM | HUMANA INC | 16.34 | 31.92B | ||
CNC | CENTENE CORP | 8.55 | 30.11B | ||
MOH | MOLINA HEALTHCARE INC | 14.22 | 17.62B | ||
HQY | HEALTHEQUITY INC | 27 | 7.31B | ||
ALHC | ALIGNMENT HEALTHCARE INC | N/A | 3.50B | ||
CLOV | CLOVER HEALTH INVESTMENTS CO | N/A | 1.84B | ||
NEUE | NEUEHEALTH INC | N/A | 55.36M |
Progyny, Inc. is a fertility benefits management company. The company is headquartered in New York City, New York and currently employs 675 full-time employees. The company went IPO on 2019-10-25. The firm specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. The company has contracts to provide coverage to approximately 6.4 million employees and their partners (known as members). The firm provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. The company provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
PROGYNY INC
1359 Broadway
New York City NEW YORK 10018 US
CEO: David Schlanger
Employees: 565
Company Website: https://www.progyny.com/
Investor Relations: https://investors.progyny.com/
Phone: 12128883124
The current stock price of PGNY is 21.44 USD. The price increased by 0.19% in the last trading session.
The exchange symbol of PROGYNY INC is PGNY and it is listed on the Nasdaq exchange.
PGNY stock is listed on the Nasdaq exchange.
16 analysts have analysed PGNY and the average price target is 27.83 USD. This implies a price increase of 29.81% is expected in the next year compared to the current price of 21.44. Check the PROGYNY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PROGYNY INC (PGNY) has a market capitalization of 1.83B USD. This makes PGNY a Small Cap stock.
PROGYNY INC (PGNY) currently has 565 employees.
PROGYNY INC (PGNY) has a support level at 20.36 and a resistance level at 21.94. Check the full technical report for a detailed analysis of PGNY support and resistance levels.
The Revenue of PROGYNY INC (PGNY) is expected to grow by 5.56% in the next year. Check the estimates tab for more information on the PGNY EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PGNY does not pay a dividend.
PROGYNY INC (PGNY) will report earnings on 2025-05-07, after the market close.
The PE ratio for PROGYNY INC (PGNY) is 37.61. This is based on the reported non-GAAP earnings per share of 0.57 and the current share price of 21.44 USD. Check the full fundamental report for a full analysis of the valuation metrics for PGNY.
The outstanding short interest for PROGYNY INC (PGNY) is 15.73% of its float. Check the ownership tab for more information on the PGNY short interest.
ChartMill assigns a technical rating of 1 / 10 to PGNY. When comparing the yearly performance of all stocks, PGNY is a bad performer in the overall market: 71.5% of all stocks are doing better.
ChartMill assigns a fundamental rating of 6 / 10 to PGNY. Both the health and profitability get an excellent rating, making PGNY a very profitable company, without any liquidiy or solvency issues.
Over the last trailing twelve months PGNY reported a non-GAAP Earnings per Share(EPS) of 0.57. The EPS decreased by -8.06% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 4.66% | ||
ROA | 8.95% | ||
ROE | 12.87% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 78% to PGNY. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 1.28% and a revenue growth 5.56% for PGNY